Foghorn Therapeutics presented data at the TPD and Induced Proximity Summit showing a Selective ARID1B degrader that could benefit up to 5% of solid tumors. Their Selective CBP degrader is progressing for potential use in EP300-mutant cancers and ER+ breast cancer by 2026. Additionally, a Selective EP300 degrader showcased efficacy in hematological malignancies. Foghorn will host a virtual investor event today, October 30, 2025. The company’s innovative protein degrader capabilities are leading the way in targeted therapy. Key program updates and scientific breakthroughs were highlighted during the event.

Read more at GlobeNewswire: Foghorn Therapeutics Announces Updates for Selective